An efficient solid phase synthetic route to 1,3-disubstituted 2,4(1H,3H)-Quinazolinediones suitable for combinatorial synthesis
摘要:
Novel, efficient solid phase chemistry has been developed for the synthesis of 1,3-disubstituted quinazolinediones. Anthranilic acids are linked to a chloroformate resin through the nitrogen, amines are coupled to the free carboxylic acid, and thermal cyclization leads to heterocycle formation and concommitant resin release resulting in traceless linkage. Copyright (C) 1996 Elsevier Science Ltd
Chemical synthesis of 1,3-disubstituted quinazolinediones
申请人:Merck Sharp & Dohme Limited
公开号:US05783698A1
公开(公告)日:1998-07-21
The present invention relates to a method for the synthesis of 1,3-disubstituted quinazolinedione derivatives which comprises: (a) reacting a haloformate functionalized polystyrene resin with a substituted anthranilic acid derivative under conditions effective to form a urethane-linkage; (b) reacting the product of step (a) with a primary amine under conditions effective to form an anthranilamide derivative; (c) heating the anthranilamide to effect intramolecular cyclization thereby liberating the 1,3-disubstituted quinazolinedione derivative from the resin into solution; and (d) isolating the 1,3-disubstituted quinazolinedione by filtration and solvent removal.
A chymase inhibitor containing as its effective ingredient a quinazoline derivative, or a pharmaceutically acceptable salt thereof, having the formula (1):
and a pharmaceutical preparation for the prevention of cardiac and circulatory system diseases derived from abnormal exacerbation of Ang II production containing the same as its effective ingredient.
一种糜蛋白酶抑制剂,其有效成分含有式(1)的喹唑啉衍生物或其药学上可接受的盐:
以及一种用于预防因血管紧张素 II 生成异常增加而引起的心脏和循环系统疾病的药物制剂,其有效成分也包含上述成分。
US5783698A
申请人:——
公开号:US5783698A
公开(公告)日:1998-07-21
US5814631A
申请人:——
公开号:US5814631A
公开(公告)日:1998-09-29
Quinazoline derivatives and applications thereof
申请人:Suntory Limited
公开号:US05814631A1
公开(公告)日:1998-09-29
A chymase inhibitor containing as its effective ingredient a quinazoline derivative, or a pharmaceutically acceptable salt thereof, having the formula (1): ##STR1## and a pharmaceutical preparation for the prevention of cardiac and circulatory system diseases derived from abnormal exacerbation of Ang II production containing the same as its effective ingredient.